MXPA04005561A - Terapias de combinacion anti-angiogenesis que comprenden derivados de piridazina o piridina. - Google Patents
Terapias de combinacion anti-angiogenesis que comprenden derivados de piridazina o piridina.Info
- Publication number
- MXPA04005561A MXPA04005561A MXPA04005561A MXPA04005561A MXPA04005561A MX PA04005561 A MXPA04005561 A MX PA04005561A MX PA04005561 A MXPA04005561 A MX PA04005561A MX PA04005561 A MXPA04005561 A MX PA04005561A MX PA04005561 A MXPA04005561 A MX PA04005561A
- Authority
- MX
- Mexico
- Prior art keywords
- pyridazine
- pyridine derivatives
- combination therapies
- angiogenesis combination
- angiogenesis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La invencion se relaciona generalmente con el uso de ciertos derivados de piridazina o piridina fundidos o no fundidos substituidos, que son inhibidores de KDR en combinacion con otros agentes quimioterapeuticos para uso en el tratamiento de enfermedades asociadas con angiogenesis anormal y/o hipermeabilidad y/o enfermedades hiperproliferativas, tales como cancer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34429401P | 2001-12-21 | 2001-12-21 | |
PCT/US2002/041145 WO2003059354A2 (en) | 2001-12-21 | 2002-12-20 | Anti-angiogenesis combination therapies comprising pyridazine or pyridine derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA04005561A true MXPA04005561A (es) | 2004-12-06 |
Family
ID=23349902
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA04005561A MXPA04005561A (es) | 2001-12-21 | 2002-12-20 | Terapias de combinacion anti-angiogenesis que comprenden derivados de piridazina o piridina. |
Country Status (7)
Country | Link |
---|---|
US (1) | US20050019424A1 (es) |
EP (1) | EP1467736A2 (es) |
JP (1) | JP2006503796A (es) |
AU (1) | AU2002364102A1 (es) |
CA (1) | CA2471314A1 (es) |
MX (1) | MXPA04005561A (es) |
WO (1) | WO2003059354A2 (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0223341D0 (en) * | 2002-10-08 | 2002-11-13 | Groningen Acad Ziekenhuis | Organic compounds |
EP1641458A2 (en) * | 2002-12-27 | 2006-04-05 | Schering Aktiengesellschaft | Pharmaceutical combinations of phthalazine vegf inhibitors and benzamide hdac inhibitors |
BRPI0408257A (pt) * | 2003-03-11 | 2006-03-07 | Novartis Ag | uso de derivados de isoquinolina para tratar cáncer e doenças relacionadas com quinase map |
US7202363B2 (en) | 2003-07-24 | 2007-04-10 | Abbott Laboratories | Thienopyridine and furopyridine kinase inhibitors |
WO2007118602A1 (en) * | 2006-04-15 | 2007-10-25 | Bayer Healthcare Ag | Compounds for treating pulmonary hypertension |
EP2373662B1 (en) | 2008-12-05 | 2014-09-24 | AbbVie Bahamas Ltd. | Thieno[3,2-c]pyridine derivatives as kinase inhibitors for use in the treatment of cancer |
US8436179B2 (en) | 2011-07-20 | 2013-05-07 | Abbvie Inc. | Kinase inhibitor with improved solubility profile |
CN104804008B (zh) * | 2015-03-27 | 2016-03-23 | 亿腾药业(泰州)有限公司 | 一种工业化生产甲磺酸特拉替尼的方法 |
KR20210019607A (ko) | 2016-06-07 | 2021-02-22 | 자코바이오 파마슈티칼스 컴퍼니 리미티드 | Shp2 억제제로서 유용한 신규한 헤테로환형 유도체 |
WO2018172984A1 (en) | 2017-03-23 | 2018-09-27 | Jacobio Pharmaceuticals Co., Ltd. | Novel heterocyclic derivatives useful as shp2 inhibitors |
AR119493A1 (es) * | 2019-07-29 | 2021-12-22 | Servier Lab | Derivados de 3,6-diamino-piridazin-3-ilo, composiciones farmacéuticas que los contienen y sus usos como agentes proapoptóticos |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CO4950519A1 (es) * | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
AR025068A1 (es) * | 1999-08-10 | 2002-11-06 | Bayer Corp | Pirazinas sustituidas y piridazinas fusionadas, composicion farmaceutica que las comprenden, uso de dichos compuestos para la manufactura de un medicamentocon actividad inhibidora de angiogenesis |
US6689883B1 (en) * | 1999-09-28 | 2004-02-10 | Bayer Pharmaceuticals Corporation | Substituted pyridines and pyridazines with angiogenesis inhibiting activity |
DOP2000000070A (es) * | 1999-09-28 | 2002-02-28 | Bayer Healthcare Llc | Piridinas y piridacinas sustituidas con actividad de inhibición de angiogénesis |
CA2427184A1 (en) * | 2000-11-22 | 2002-05-30 | Novartis Ag | Combination comprising an agent decreasing vegf activity and an agent decreasing egf activity |
-
2002
- 2002-12-20 MX MXPA04005561A patent/MXPA04005561A/es unknown
- 2002-12-20 US US10/498,935 patent/US20050019424A1/en not_active Abandoned
- 2002-12-20 JP JP2003559516A patent/JP2006503796A/ja active Pending
- 2002-12-20 WO PCT/US2002/041145 patent/WO2003059354A2/en active Application Filing
- 2002-12-20 AU AU2002364102A patent/AU2002364102A1/en not_active Abandoned
- 2002-12-20 EP EP02798573A patent/EP1467736A2/en not_active Withdrawn
- 2002-12-20 CA CA002471314A patent/CA2471314A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2006503796A (ja) | 2006-02-02 |
AU2002364102A8 (en) | 2003-07-30 |
CA2471314A1 (en) | 2003-07-24 |
WO2003059354A2 (en) | 2003-07-24 |
AU2002364102A1 (en) | 2003-07-30 |
US20050019424A1 (en) | 2005-01-27 |
EP1467736A2 (en) | 2004-10-20 |
WO2003059354A3 (en) | 2003-11-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUS1700003I1 (hu) | Pirimidinamin-származékok és ezeket tartalmazó gyógyászati készítmények, mint angiogenézis modulátorok | |
MXPA04005561A (es) | Terapias de combinacion anti-angiogenesis que comprenden derivados de piridazina o piridina. | |
AU2003220970A1 (en) | Diamino-pyrimidines and their use as angiogenesis inhibitors | |
MY145077A (en) | Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | |
TW200738724A (en) | Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | |
EP1432714A4 (en) | CHEMICAL COMPOUNDS | |
RS48804A (en) | Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers | |
MY122771A (en) | Heterocyclically substituted benzimidazoles, their preparation and use thereof | |
MXPA04004064A (es) | Derivados heteroaromaticos de carboxamida para el tratramiento de la inflamacion. | |
HK1096392A1 (en) | Substituted heterocycles | |
IL146482A (en) | Tek antagonists | |
HK1046912B (zh) | 取代的皂苷酸基及它們的用途 | |
AP2004002995A0 (en) | Combination therapy for the treatment of cancer | |
WO2004009610A3 (en) | Use of nucleoside compounds for nonsense suppression and the treatment of genetic diseases | |
PL372179A1 (en) | Fused tricyclic heterocycles useful for treating hyper-proliferative disorders | |
MXPA03008423A (es) | Agonistas del receptor nicotinico para el tratamiento de enfermedades inflamatorias. | |
YU102503A (sh) | Kondenzovani pirimidinski dhfr inhibitori kao antibakterijska sredstva | |
IL152097A0 (en) | Use of pyrazole derivatives for treating infertility | |
WO2003090680A3 (en) | Novel phenyl derivatives as inducers of apoptosis | |
MXPA03000979A (es) | Moleculas tipo receptor de complemento c3b/c4b y usos de las mismas. | |
MXPA04003910A (es) | Uso de irbesartan para la preparacion de medicamentos que son utiles para la prevencion o tratamiento de hipertension pulmonar. | |
UA85187C2 (en) | 2-aminobenzoyl derivatives | |
ATE360062T1 (de) | Deglykosilierte fragmente der kringle 1-5 region von plasminogen und verwendungsverfahren | |
MXPA04004757A (es) | Uso de una ascomicina para el tratamiento de blefaritis. | |
AU6301398A (en) | Arrestable therapeutic viral agent |